ADAR1 Capital and Executives Buy InMed Shares as Merger Buzz Builds: Is the Stock Poised for a Resurgence?

ADAR1 Capital’s Holding Signals Cautious Optimism

The latest form 3 filing from ADAR1 Capital Management, LLC reveals that the private‑investment fund now holds 331,449 shares of InMed Pharmaceuticals at a valuation of $1.73 per share. The stake is significant for a fund that typically invests in early‑stage biotech, suggesting that the manager sees a meaningful upside in InMed’s cannabis‑based pipeline. Because the shares are held directly and not through a nominee, ADAR1’s exposure is fully transparent, giving other investors a clear benchmark for potential value.

Insider Activity Follows a “Buy‑the‑Dip” Narrative

The company’s own insiders have been purchasing a sizeable block of employee‑stock options (ESOPs) in mid‑December. Executives such as the CEO, CFO, and COO have all bought 18,000 to 35,000 option shares, with the total post‑transaction holdings topping 49,050 shares for the CEO alone. The price point was zero, reflecting the exercise of previously granted options, but the sheer volume of purchases indicates that leadership believes the stock is undervalued relative to its long‑term prospects. This pattern contrasts sharply with the earlier option expirations in December, which reduced holdings for several executives, suggesting a shift from risk‑neutral to bullish sentiment as the merger with Mentari moves forward.

Implications for Investors

The confluence of a large private‑fund holding and aggressive insider buying can be read as a two‑tier endorsement. First, ADAR1’s 331,449 shares provide an institutional stake that could stabilize the stock price, especially given the company’s recent negative earnings multiples and volatile trading. Second, insider purchases demonstrate confidence in the upcoming Merger Agreement with Mentari Therapeutics and the anticipated capital raise through a private placement. For value‑oriented investors, the current price of $1.61 (down 37 % year‑to‑date) sits near the 52‑week low of $0.575, creating a potentially attractive entry point if the merger is successful.

Risk Factors and Market Sentiment

Despite the bullish insider moves, the market sentiment remains neutral (-0) and buzz is modest at 10.45 %. This suggests that the broader community has not yet fully absorbed the merger news. Moreover, the company’s price‑to‑earnings ratio is negative (-0.67), and its annual revenue growth is underwhelming, indicating that the upside will largely depend on Mentari’s drug development milestones and successful regulatory approvals. Investors should therefore monitor the Merger Agreement’s closing conditions and the timeline for the private placement, as delays could temper the optimistic insider narrative.

Bottom Line

ADAR1 Capital’s sizeable stake combined with a flurry of insider option purchases paints a picture of growing confidence in InMed’s future trajectory. If the merger with Mentari delivers on its promise, the stock could see a sharp rebound from its current low. Conversely, any setback in the merger or regulatory approval could leave the shares exposed to the volatility that has plagued the company’s valuation. For seasoned biotech investors, the next few months will be decisive in determining whether InMed’s cannabis‑based platform can translate into tangible shareholder value.